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Abstract
Our long-term goal is to develop a monodisperse high molecular weight hemoglobin-based
oxygen carrier (HBOC) for clinical care. One short-term aim is to ligate hemoglobin (Hb) molecules
to a dendritic scaffold utilizing “click-chemistry”. Towards this goal, we have genetically modified
the C-terminus of one of the α subunits of a di-α globin to contain the S. aureus sortase A
recognition sequence (LPETG) and we have expressed the modified globin in E. coli. Here, we
demonstrate that these Hbs can be site-specifically functionalized through sortase-mediated
ligation of peptides containing dibenzocyclooctyne (DBCO). We further demonstrated proof-ofconcept by conjugating an azide-funtionalized peptide with a fluorescent tag, 6carboxyfluorescein (6-FAM) to Hb(DBCO). Additionally, work has been done to crystallize Hb with
a site-specific mutant N108K, which promotes T-state stability of Hb (low oxygen affinity). Cellfree Hb is known to have high oxygen affinity and by determining the structural basis for
improving T-state stability in our novel Hbs we hope to design our HBOC with ideal characteristics
for reversible oxygen binding. This work establishes that we can functionalize hemoglobin with
“click-chemistry” groups such as cyclooctyne, and conjugate that group to an azide with the
ultimate goal of decorating azide-functionalized dendrimers with hemoglobin molecules to
transport and exchange oxygen in the body.
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Introduction
Blood transfusions. Currently, blood transfusion is the standard of care for blood loss.
Hospitals rely on blood donations to provide this life-saving treatment, and many operations
cannot be performed without a blood transfusion. According to the World Health Organization
(WHO), in high income countries blood transfusions are most commonly performed for
cardiovascular and transplant surgery, trauma, and various hematological malignancies. In low
income countries blood transfusions are most needed for pregnancy-related complications and
severe childhood anemia1.
Blood transfusions require donations from healthy volunteers and this poses significant
challenges. In many low and middle-income countries, the current level of blood donations does
not meet the need for blood transfusions. High-income countries have a whole blood donation
rate of 32.1 donations per 1,000 population per year, however, in low-income countries the
donation rate is 4.6 donations per 1,000 population per year 1 (Figure 1). In addition, there are
low retention rates of blood donations because of blood transfusion safety. A number of

Figure 1. Whole blood donations per 1,000 population in 2013 1. Source: World Health
Organization.
1

countries have a high percentage of transfusion-transmissible infections in the population, but
not enough adequate resources to screen for them 1. Identification of transfusion-transmissible
infections, as well as the expiration of donated blood results in a discard rate ranging from 7% 11% of total donated blood around the world1. In the US, while blood donations meet the
requirement, they rarely exceed it so storage of blood donations is not feasible 2.
Of the many functions of blood, one of the most essential is the transportation of
oxygen from our lungs to our tissues. Without oxygen, cells are unable to produce the energy
necessary for our body to function. Loss of blood causes a deprivation of oxygen to cells and
thus requires an immediate response, such as a red blood cell transfusion. The protein
responsible for oxygen transport, hemoglobin (Hb), is housed inside the red blood cell, and so
when a patient is given red blood cells, they are also given Hb. Hb is a 64 kDa protein with 2 
and 2  subunits. Each subunit contains a hemin group which chelates to Fe2+ and binds to
oxygen. The red blood cell provides protection to Hb, separates Hb from reactive species, and
provides the enzymes and small molecules necessary for Hb to function3,4. In addition, the red
blood cell poses some challenges to blood transfusions. The antigens on the surface of red
blood cells require blood type matching and red blood cells cannot be mass produced; they
must be donated by healthy volunteers.
An alternative to red blood cell transfusions. In order to alleviate some of the demand
for blood transfusions, researchers have been working to develop an alternative to red blood
cell transfusions. The function of this therapeutic would be to transport oxygen and so one of
the approaches has been to modify the natural carrier of oxygen, hemoglobin, and therefore
develop a hemoglobin-based oxygen carrier (HBOC). By modifying Hb to function properly cell2

free, patients could be given this therapeutic to alleviate immediate concerns of oxygen
transportation. While a hemoglobin-based therapeutic could not address all of the functions of
blood, it would reduce the need for red blood cell transfusions for patients dealing with trauma
or other conditions involving acute blood loss. Of the many challenges associated with HBOCs,
one is Hb’s small size relative to the red blood cell. Cell-free Hb is small enough to extravasate
through the blood vessel wall and into the interstitial space between endothelial cells and
smooth muscle5. In this space nitric oxide is a signaling molecule that relaxes smooth muscle
cells6. When oxygenated, Hb mixes with nitric oxide, nitric oxide enters the distal pocket, and is
converted to nitrate (NO3-) while Hb is converted to methemoglobin (metHb)7. When this
occurs, smooth muscle is unable to receive the signal to relax which results in an increase in
mean arterial blood pressure and other smooth-muscle effects such as gastrointestinal
discomfort8. These undesirable effects can be reduced by increasing the molecular weight of
the cell-free Hb 9 (Figure 2).
In addition to increased extravasation, the Hb 2 2 heterotetramer has reduced stability
in a cell-free environment which results in its dissociation into  heterodimers. These dimers
are small enough to be rapidly cleared by glomerular filtration in the kidneys or by a Hb
scavenging receptor in the liver. As  dimers, Hb is quickly cleared from the blood and
therefore nonfunctional10. Increased renal filtration can also result in renal damage caused by
the overload of the glomerular filtration capacity in the kidneys11,3,4. For this reason, Hb stability
and molecular weight need to be addressed when developing a functional HBOC.
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Another problem associated with cell-free Hb is the auto-oxidation of the iron chelated
in the heme group from Fe2+ to Fe3+. The oxidation to Fe3+ forms metHb which is unable to
transport and exchange oxygen12. Heme loss is also accelerated in the methemoglobin state
because of a reduction in stability13. For cell-free Hb the oxidation reaction occurs over a few
hours and is essentially irreversible, whereas in the red blood cell there are antioxidants such as
NAD(P)H that maintain Hb in the reduced Fe2+ state14.
Strategies for developing HBOCs. The goal of HBOC development is to modify Hb so that
it can function properly outside of a red blood cell. Many HBOCs have been tested in clinical
trials but none has been approved by the FDA for use in humans. While there are many
challenges associated with cell-free Hb, through rational design and protein modification these
challenges can be overcome. In addition, by understanding the characteristics of HBOCs that
4

have been developed in the past, we can learn from both successes and failures. The three
main strategies for modifying Hb have been polymerization, conjugation, and cross-linking3,15
(Figure 3).

Polymerized Hb
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α
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with this approach, retention times increased from the
rapid clearance of cell-free Hb to a half-life of 16-20 hours
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β

α

α

β

to this approach is that the reaction, which links surface
lysines on neighboring Hb together, is non-specific, and so

Conjugated Hb
PEG

PEG
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β

α

α
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for Hemopure and 24 hours for Polyheme10. The drawback

the resulting product is a heterogeneous mixture of
polymers10,16.
Conjugation, similar to polymerization, increases

PEG

Figure 3. Strategies for development
of HBOCs. Non-specific polymerized
Hb (top), chemically or genetically
cross-linked Hb (middle), Hb
conjugated with PEG (bottom).
Adapted from Stowell et al.3

the apparent molecular size of Hb in order to increase
retention time and to reduce extravasation. Sangart, Inc
used this approach to develop Hemospan, which was
made by conjugating polyethylene glycol to Hb by sitespecific addition17. Hemospan was found to have a half5

life of 14-23 hours in patients, but it also appeared that Hemospan was eliminated from the blood
by the scavenger receptor CD16310. In addition Hemospan had an overall high oxygen affinity and
an increase loss of hemin and so while it went through early clinical trials, its development was
eventually terminated15,17.
Lastly cross-linking Hbs subunits, both chemically or genetically, increases stability and
prevents dissociation of Hb into heterodimers. HemAssist, developed separately by Baxter and
the US army, chemically cross-linked the  subunits in purified human Hb with bis(3,5dibromosalicyl) fumarate. This approach increased stability and resulted in a half-life of 2.1-4.3
hours in humans10. When tested more rigorously in humans, however, results indicated
vasoconstriction and ultimately increased adverse effects in comparison with the standard blood
transfusion18. Optro, developed by Somatogen, genetically cross-linked the  subunits creating a
di- subunit with a single glycine inserted between the  subunits19. While this produced a stable
hemoglobin, other problems were still present including high oxygen affinity, nitric oxide
scavenging, auto-oxidation, and hemin loss20.
Developing a monodisperse HBOC. While previous HBOCs have shown many advantages,
each had its disadvantages. The most prominent problems are Hb stability in the blood and
nitric oxide scavenging. To address these problems our strategy has been to develop a
polymeric Hb molecule that has a defined molecular weight and size. Based on evidence shown
in Figure 1, increased molecular weight of Hb will reduce mean arterial pressure caused by
nitric oxide scavenging. In addition, creating a molecule with one size will eliminate the smaller
molecular weight products that are associated with increased extravasation and blood pressure
elevation. Initially, the strategy for this work was to develop a recombinant single-chain Hb
6

(scHb) in three main steps. The first was to create a circularly permuted  globin by modifying
the N and C-terminal sites21. The second was to then link the  and  globins together to create
a single chain  dimer (sc-cp) and then lastly to link the -globins together by inserting a
single glycine linker (Figure 4)22. We envisioned this sc-Hb as a monomer unit to be used in the
construction of a recombinant poly-Hb of defined molecular weight.

Figure 4. Scheme for scHb development. -globin and circularly permuted  globins were linked
together to create sc-cp. This was followed by linking the two dimers together with a glycine
linker to create scHb.19,20
The scHb was successfully expressed, however, in a very low protein yield22. This was
mitigated by adding additional stabilizing mutants β G16A, β H116I, α G15A, and β K82D, which
were reported by Graves et al. and Weickert et al23,24 to increase stability and expression yields
of globins. Unfortunately, even with the addition of these stabilizing mutations, the expression
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yield remained too low for this approach to poly-Hb to be economically feasible. Therefore, a
new approach needed to be taken to create a Hb polymer with a defined molecular weight.
Sortase-mediated monodisperse HBOC. The approach we have taken combines genetic
and chemical modifications of Hb to develop an HBOC polymer that is a defined molecular
weight and size and can also be produced on a large scale. Our method is based on the concept
of decorating a central scaffold with functional Hb molecules. With highly efficient click
chemistry Hb molecules will be attached to a commercially available azide dendrimer, which
will contain 4-12 sites for Hb attachment (Figure 5). The attachment will be achieved with a
cyclo-alkyne azide addition which needs no metal catalyst but is instead catalyzed by the strain
produced from the cyclo-alkyne25.

Figure 5. Scheme for development of oligomeric, monodisperse HBOC. A cyclooctynemodified Hb molecule will be added to a azide functionalized dendrimer.

For this method to work, Hb needs to contain a cyclo-alkyne tag which will be added
with the help of the transpeptidase, sortase A. Found in many bacteria, but specifically in S.
aureus, sortase attaches proteins to the peptidoglycan cell wall by recognizing a LPXTG motif,
8

cleaving between the threonine and glycine to form a thioester intermediate where an
incoming N-terminal glycine can act as a nucleophile to form a new peptide bond26.
In this way, sortase can attach small peptides with an N-terminal glycine to any protein
containing the LPXTG motif (Figure 6). With this in mind we synthesized Hb to contain a C-

Figure 6. Sortase-mediated ligation. Sortase A recognizes the LPETG motif on a protein,
forms an enzyme-bound thioester intermediate which is attacked by a glycine nucleophile
derivatized with a cyclooctyne.
terminal LPETG sortase A tag on the  subunit. With sortase A as a catalyst, we added a small
peptide derivatized with dibenzocycloocytne [GGK(DBCO)] to Hb (Figure 8). To create a more
stable construct we further modified Hb to be di- by covalently linking the  subunits with a
LPETGG(H)6

glycine linker. Lastly, we included the 4
stabilizing mutations mentioned above (β

β

α

α

β

G16A, β H116I, α G15A, and β K82D) and
included a hexa-histidine tag for purification
(Figure 7). These modifications produced a
stable Hb molecule that can be easily
purified as well as modified by sortase A
(Figure 8).

Figure 7. Hb building block. A novel
recombinant Hb was designed to include
a glycine linker between the α subunits
as well as a sortase tag followed by a
hexa-histidine tag on the C-terminus of
the di- α subunit.
9

Figure 8. Sortase-mediated Hb ligation. Sortase A recognizes the LPETG motif on Hb, forms
an enzyme-bound thioester intermediate which is attacked by a glycine nucleophile
derivatized with a cyclooctyne.

Modulating oxygen affinity. In addition to working to develop an HBOC with a high
molecular weight, we also wanted to focus on the other physical properties of Hb to ensure our
product has optimal functional properties. To transport oxygen efficiently, Hb has 2
conformations. The first is the high oxygen affinity relaxed state (R-state) and the other is the
low oxygen affinity tense-state (T state). These 2 conformations allow R-state Hb to bind to
oxygen in the lungs and then to release oxygen by switching to the T state when it reaches
various tissues in our body. Hb’s conformational changes are modulated by many allosteric
regulators including 2,3-bisphosphoglyceric acid (2,3-BPG), protons, and CO2 3. One regulator,
2,3-BPG, is found at high concentration in red blood cells and is able to promote the change
from R-state to T-state4. Cell-free Hb, however, is not regulated in this way because of the
much lower concentration of 2,3-BPG in the blood plasma. For this reason, cell-free Hb has high
oxygen affinity, which reduces the release of oxygen compared to Hb in red blood cells27.
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To alleviate this problem, mutations have been made to increase T-state stability in Hb.
One in particular, βN108K, reduces Hb’s oxygen affinity to a value similar to that of whole
blood28. In order to understand how this mutation affects the stability of the R and T states in
our circularly permuted (cp) Hbs, work has been done to crystallize N108K in the -cp Hb
construct. With X-ray diffraction data, the structure of the modified Hb can be solved revealing
the structural details for this Hb variant, which may be different from those observed in the
wild-type Hb. So far, we have been unable to get good resolution on X-ray diffraction data.
Many crystal conditions have been tested but with further optimization X-ray diffraction data
could be a possibility.
The work described in this thesis suggests that our new approach shows merit in
achieving our long-term goal. We have successfully expressed and purified di--cp sHb, ligated
DBCO to it with sortase A, and conjugated an azide functionalized peptide to di-(DBCO)-cp
sHb. Overall, the development of our polymeric HBOC has focused on reducing the effects of
nitric oxide scavenging and increasing hemoglobin T-state stability. Through a combination of
genetic modifications and mutations as well as chemical adaptations we plan to develop an
oligomeric monodisperse product that can be used for acute blood replacement. Continued
work is necessary to produce a poly-Hb in high yield and to optimize its properties. The
development of a safe and effective HBOC will address the need for an alternative to red blood
cell transfusions and therefore has the potential to save lives.
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Materials and Methods
Protein Expression
Gene design. A di- subunit with a sortase A tag (LPETG) followed by 6 histidines on the
C-terminal end was synthesized and cloned into a pUC plasmid which contained circularlypermuted  Hb subunit with 4 stabilizing mutations (β G16A, β H116I, α G15A, and β K82D) (Di cp- sHb). The gene was then subcloned into an expression vector derived from the pDLIII13e plasmid described by Hoffman et al.29.
Transformation. The expression plasmid was transformed into chemically competent
BL21 E. coli cells by adding 1 l of the plasmid to 50 l of E. coli cells, which were then placed
on ice for 30 minutes. Cells were incubated at 42C for 1 minute, immediately placed back on
ice for 3 minutes, re-suspended in 1 mL Luria Bertani (LB) broth (10 g/L tryptone, 5 g/L yeast
extract, 10 g/L NaCl), and incubated at 37C for 45 minutes in a shaker. Following this
outgrowth, increasing amounts (25, 50, 100 l) of transformed cells were added onto 3 LB
tetracycline agar plates (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 14 g/L agar, 23 M
tetracycline, pH 7.0) and incubated for 26 hours at 37C. Two distinct colonies were picked and
placed in 10 mL LB-tetracycline (23 M tetracycline) broth and incubated at 37C for 12 hours
in a shaker to make seed stocks (1:1 overnight broth:50% v/v glycerol), which were then stored
at -80C.
Protein expression. Two different protein constructs were expressed, the first was  cp Hb 4SM with the additional mutation N108K (N108K Hb) and the second was di- cp- sHb
(sHb). The first, N108K Hb, was previously transformed into BL21 E. coli cells and seedstocks

12

were obtained from Johann Sigurjonsson. The cells were first grown by inoculating 10 mL LBtetracycline (23 M tetracycline) with 1 L seed-stock and incubated at 37C for 12 hours in a
shaker. Cells were then added to 1 L of Terrific Broth (TB) medium [12 g/L tryptone, 24 g/L yeast
extract, 4% (v/v) glycerol, 2.31 g/L KH2PO4, 16.43 g/L K2HPO4/trihydrate] with 23 M
tetracycline and grown at 37°C with shaking at 200 rpm and induced with 1 mM isopropyl βthiogalactopyranoside (IPTG) when the optical density at 600 nm reached 1.8. The temperature
was reduced to 33.5C and cells were grown for an additional 5 hours, with the addition of 2 mL
of a stock hemin solution (12.5 g/L hemin, 200 mM NaOH) added every hour for a total of 0.05
g of hemin added per liter. Cells were harvested by centrifugation at 5,000 x g for 10 min at 4°C
(Thermo Scientific Sorvall Lynx 4000) and frozen in liquid nitrogen to be stored at -80°C.
The second construct, sHb, was transformed as described above and cells were grown
and induced as described for N108K Hb, except that the temperature was kept constant at
33.5°C and during induction 100mL of 20% (w/v) glucose was also added in addition to ITPG to
increase expression.

Protein Purification
Cell lysis. Cell pellets were thawed and resuspended in lysis buffer [N108K Hb (50 mM
Tris-HCl, pH 8.5, 17 mM NaCl); sHb (20 mM Tris-HCl, pH 8.5, 300 mM NaCl, 10 mM imidazole)].
Cells were sonicated (power output: 5 @ 50% duty cycle, Branson Intruments, Inc. Sonifier,
model 450) on ice for a total of 90 seconds (3 x 30 sec pulses) with 60 seconds rest between
every 30 second pulse. The resulting lysate was clarified by centrifugation at 40,000 x g for 30
min at 4°C. For the N108K Hb, 2 mM Zn(OAc)2 was added to the lysate and an additional
13

centrifugation was performed at 40,000 x g for 30 min at 4°C. Supernatants from each construct
were collected and filtered through a 0.22 m cellulose acetate syringe filter.
Immobilized metal affinity chromatography (IMAC). To purify Hb constructs a column
was packed with 10 mL GE Healthcare Fast Flow Chelating Sepharose resin. The column was
washed with 4 column volumes (CV) of 200 mM NaCl, 2 CV 20 mM Zn(OAc) 2, and 6 CV 200 mM
NaCl. N108K Hb lysate was then loaded onto the column and washed with 8 CV 20 mM Tris-HCl,
pH 8.5, 0.5 M NaCl, then 2 CV 250 mM Tris-HCl, pH 8.5, followed by 6 CV 20 mM Tris-HCl, pH
8.5. The protein was eluted with 20 mM Tris-HCl, pH 8.5, 15 mM EDTA.
For the sHb construct the column was prepared with the same resin and washed with 4
CV of 0.2 M NaCl, 0.5 CV 0.2 M NiSO4, 4 CV 20 mM NaOAC, 0.5 M NaCl pH 4, and 5 CV 0.2 M
NaCl. Lysate was loaded onto the column and washed with 4 CV lysis buffer (20 mM Tris-HCl,
pH 8.5, 300 mM NaCl, 10 mM imidazole), followed by 4 CV wash buffer (20 mM Tris-HCl, pH 8.5,
150 mM NaCl, 50 mM imidazole). The protein was eluted with 20 mM Tris-HCl, pH 8.5, 50 mM
NaCl, 300 mM imidazole.
Dialysis. Buffer exchange was performed by adding the protein solution to Fisherbrand
dialysis tubing with a molecular weight cutoff (MWCO) of 6,000-8,000 Da. Tubing was placed in
2 L of Buffer A (20 mM Tris-HCl, pH 8.5) and incubated for 24 hours at 4˚C. Hb samples were
collected and concentrated to less than 1 mL with Amicon Ultra concentrators with 10,000
MWCO.
Anion-exchange chromatography. Protein was further purified with a Mono-Q 10/100
GL strong anion exchange column (8 mL CV). Protein samples from IMAC were centrifuged for
10 min at 10,000 x g (Eppendorf centrifuge 5415D) to pellet any insoluble impurities. The
14

Mono-Q 10/100 column was equilibrated with 5 CV water, 1 CV Buffer A, 1 CV Buffer B (20 mM
Tris-HCl, 0.5 M NaCl, pH 8.5), then 5 CV Buffer A at 4 ml/min. Protein was then injected onto
the column and eluted with a gradient that started at 100% Buffer A, 0% Buffer B and increased
to 100% Buffer B and 0% Buffer A over 20 CV. Eluent, which was monitored at 280 nm, was
collected, and samples with a red tint were kept. The presence of hemoglobin in the samples
was confirmed with UV-Vis spectroscopy (see below).
Size exclusion chromatography. The  cp- Hb 4SM N108K construct was further
purified with an Amersham Pharmacia Biotech Superdex 75 HR 10/30 column (24 mL CV). The
column was equilibrated with 2 CV water and then 2 CV ammonium acetate, pH 8.5 at 0.5
mL/min. The protein sample was centrifuged for 10 min at 10,000 x g prior to injection onto the
column. Eluent with a red tint was collected.

Protein Characterization
UV-Vis spectroscopy. Purifed Hb samples were characterized by UV-visible spectroscopy
with a Thermo Scientific Nanodrop 1000 Spectrophotometer. The absorbance of the Soret band
at 415 nm was measured to calculate Hb concentration (the extinction coefficient of oxy-Hb =
12,500 M-1 cm-1).
SDS-PAGE. Samples were prepared by 1:1 dilution with 2X Bio-Rad Laemmli sample
buffer. Samples were added to wells in a stacking gel with a 15% resolving layer [15% (v/v)
acrylamide, 375 mM Tris-HCl, pH 8.8, 0.1% (v/v) SDS, 0.1% (v/v) APS, TEMED] and a 5% stacking
layer [5% (v/v) acrylamide, 125 mM Tris-HCl, pH 6.8, 0.1% (v/v) SDS, 0.1% (v/v) APS, TEMED]. To
track protein migration Thermo Scientific PageRuler Prestained Protein Ladder was added to an
15

empty lane. Electrophoresis was carried out for 30 min at 90 V, which forced the samples to
travel through the stacking layer. The voltage was increased to 150 V until the samples had
traveled to the bottom of the gel. The gel was removed and then imaged. For fluorescence
imaging the gel was immediately scanned using a Bio Rad Gel Doc EZ imager. Following the
image, the gel was incubated in Coommassie protein stain [50% (v/v) methanol, 10% (v/v) glacial
acetic acid, 0.1% (w/v) Coomassie Brilliant Blue R250], followed by destain (1:3:4 glacial acetic
acid:methanol:water solution ). Images of Coomassie-stained gels were obtained with a Bio Rad

Gel Doc EZ imager.
Protein mass spectrometry. All electrospray ionization mass spectrometry (ESI-MS)
analysis were done on an Advion expression CMS instrument attached to a Thermo Scientific
Dionex Ultimate 3000 HPLC system. Protein samples were analyzed by ESI-MS on an Aeris 3.6
m WIDEPORE XB-C8 200 Å LC column using Method A [Solvent A = 5% acetonitrile, 0.1%
formic acid; Solvent B = acetonitrile, 0.1% formic acid (mobile phase). Flow rate = 4 mL/min.
Gradient = 10% solvent B, 90% solvent A (0.0-2.0 min), 10% solvent B to 90% solvent B (2.0-12.0
min), hold 90% solvent B (12.0-14.0 min), 90% solvent B to 10% solvent B (14.0-14.1 min),
equilibrate back to 10% solvent B, 90% solvent A (14.1-17.0 min)]. Spectra were analyzed with
MestReNova and reconstructed with Analyst.

Conjugation and ligation of sHb
Synthesis of GGK(DBCO). The peptide Fmoc-GGK, obtained from Sierra Reed and John
Antos, was ligated to dibenzocyclooctyne (DBCO), deprotected and purified. To ligate FmocGGK to DBCO 5.49 mol DBCO-NHS was mixed with 11 mol Fmoc-GGK, 32.9 mol DIPEA, and
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N-methyl-2-pyrrolidone (NMP) in a total reaction volume of 100 l. The reaction mixture was
incubated at 25C for 25 min and product formation was confirmed with ESI-MS on a Kinetex
2.6 m, C18 100 Å LC column (100 x 2.1 mm, C18, Phenomenex) using Method B [Solvent A =
5% acetonitrile, 0.1% formic acid; Solvent B = acetonitrile, 0.1% formic acid (mobile phase).
Flow rate = 0.4 mL/min. Gradient = 100% solvent A (0.0-1.0 min), 0% solvent B to 90% solvent B
(1.0-7.0 min), hold 90% solvent B (7.0-9.0 min), 90% solvent B to 100% solvent A (9.0-9.1 min),
equilibrate at 100% solvent A (9.1-12.0 min)] (Expected mass for Fmoc-GGK(DBCO) = 768.3 Da,
observed mass = 768.3 Da). Product was then deprotected by mixing with 20% (v/v) piperidine
followed by incubation at 25C for 45 min. The reaction was monitored by ESI-MS on the
Kinetex C18 column using Method B and determined to be complete by 45 min (expected mass
for GGK(DBCO) = 546.3 Da, observed mass = 547.3 Da). The reaction mixture was then purified
with HPLC on the Luna 5u C18(2) 100 Å column (250 x 10 mm) (semi-prep, Phenomenex) using
Method C [Solvent A = 5% acetonitrile, 0.1% formic acid; Solvent B = acetonitrile, 0.1% formic
acid (mobile phase). Flow rate = 4 mL/min. Gradient = 10% solvent B, 90% solvent A (0.0-2.0
min), 10% solvent B to 90% solvent B (2.0-15.0 min), hold 90% solvent B (15.0-17.0 min), 90%
solvent B to 10% solvent B (17.0-17.1 min), equilibrate back to 10% solvent B, 90% solvent A
(17.1-20.0 min)]. Eluent was monitored at 280 nm as well as 300 nm and the peak eluting at
about 8.5 min was collected. Formic acid and acetonitrile were removed from the collected
sample by rotary evaporation and the sample was then frozen over dry ice and lyophilized to
remove any remaining solvent. The purified peptide was resolubilized in 100 l water and 20 l
DMSO and its identity was confirmed by LC-ESI-MS with Method B as described above (Figure
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A1 and A2). Final concentration of the GGK-DBCO stock solution was determined using UV-Vis
at λmax = 309 nm and a molar extinction coefficient of 12,000 M -1 cm-1.
Sortase-mediated ligation. Di- cp- sHb was ligated to the peptide GGK(FITC) (FITC =
fluorescein isothiocyanate) as a proof-of-concept prior to ligation to GGK(DBCO). In ligation
reactions 50 M di- cp- sHb was mixed with 100 M GGK(FITC) (obtained from Sierra Reed
and John Antos) and 5 M sortase A heptamutant in sortase buffer (500 mM Tris-HCl, pH 7.5,
1.5 M NaCl, 100 mM CaCl2). The reaction was incubated for 150 min at 25 C with samples
removed and denatured every 30 min for SDS-PAGE and mass spectrometry. The di- cp- sHb
ligation to GGK(DBCO) was repeated in the same manner except that the reaction was
monitored for 120 min.
Purification of di-(DBCO) cp- sHb product. Di-(DBCO) cp- sHb was purified from the
sortase-mediated ligation reaction mixture with IMAC. The IMAC column [3 mL Thermo
Scientific HisPur Ni-NTA (nitrilotriacetic acid )resin] was prepared by washing the packed resin
with 10 CV water followed by 10 CV loading buffer (20 mM Tris pH 8.0, 150 mM NaCl, 10 mM
imidazole). The reaction mixture was then loaded onto the equilibrated column and washed
with 10 CV loading buffer. Di-(DBCO) cp- sHb was then eluted with a low imidazole buffer (20
mM Tris pH 8.0, 150 mM NaCl, 50 mM imidazole) and di- cp- sHb was eluted with a high
imidazole buffer (20 mM Tris pH 8.0, 150 mM NaCl, 250 mM imidazole). Eluents were initially
characterized with UV-Vis spectrometry and then samples containing hemoglobin were
characterized with SDS-PAGE and mass spectrometry.
Cyclooctyne azide conjugation. Purified di-(DBCO) cp- sHb was then conjugated to
fluorescent 6-FAM (fluorescein)-azide by adding 20 M di-(DBCO) cp- sHb to 10 M 6-FAM18

azide (obtained from Sierra Reed and John Antos). The reaction was incubated at 25C for 60
min and samples were taken and denatured every 15 min for analysis with SDS-PAGE and mass
spectrometry.

Crystallization
Crystal trays. A total of 30 crystal trays were made and each tray was made with varying
buffer conditions, protein concentration, and temperature (Table A1). Initially, the top of each
well was coated with petroleum jelly to help create a seal and according to the conditions, and
500 l of the specified buffer was placed in each well in a 24-well tray. On a cover slide, 1-2 l
of buffer was mixed with 1 l of protein solution, producing a single drop. When specified in
Table 1, 40 l of Hampton Research Al’s Oil was added on top of the protein:buffer drop. The
cover slide was then flipped over and placed on the top of the well, where the slide was then
pushed down and turned to ensure a good seal. The tray was placed in a dark area at the
specified temperature and crystal growth was monitored by observation using a Motic digital
light microscope.
X-ray diffraction. Crystals were collected based on size, structure, and color. To collect a
crystal, 15% glycerol cryo buffer (specified buffer with 15% glycerol) was added to the crystal
slide followed by 30% glycerol cryo buffer (specified buffer with 30% glycerol). Crystals were
then captured with a crystal loop and quickly transferred to liquid nitrogen. Crystals were
stored in liquid nitrogen until diffraction data was collected. X-ray diffraction data were
collected on Rigaku XtaLAB crystal X-ray diffractometer. A total of 3 images were collected with
steps of 30 degrees.
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Results
With the goal of developing a high molecular weight monodisperse hemoglobin, we
expressed 2 Hb constructs to study further. The first construct, N108K Hb, was expressed in
order to determine the structure of the low oxygen affinity mutant by X-ray crystallography.
The second construct, sHb, was expressed to test the efficacy of sortase-mediated ligation,
followed by azide-alkyne conjugation.
Protein expression and purification. Both protein constructs were successfully expressed
in BL21 E. coli cells. After the IMAC purification step N108K Hb was recovered in a crude yield of
35 mg/L. N108K Hb was further purified with anion exchange chromatography followed by size
exclusion chromatography to >95% homogeneity based on densitometry performed on SDSPAGE gels (Figure 9).

Figure 9. Purification analysis of N108K Hb by SDS-PAGE. N108K Hb was purified first with
IMAC (Step 1), followed by anion exchange chromatography (Step 2) and size exclusion
chromatography (Step 3).
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The sHb expression was significantly
lower than that for N108K Hb, with a crude
yield of 1.035 mg/L after IMAC. With the
hexa-histidine tag, however, we were able
to get good purification after 2 steps: IMAC
followed by anion exchange
chromatography. The sHb was purified to
98% homogeneity based on densitometry
(Figure 10).

Figure 10. Purification analysis of sHb with
SDS-PAGE. sHb was purified from lysate
using IMAC (Step 1), followed by anion
exchange chromatography (Step 2)

Sortase-mediated ligation of GGK(FITC) to sHb. In order to verify that the sortasemediated ligation would occur with Hb, we wanted to test the reaction with a fluorescent
probe so that the reaction progress could be easily visualized. Thus, we initially tested this
reaction by combining sHb with GGK(FITC) and sortase A (Figure 11). The reaction occurred for

Figure 11. Sortase-mediated ligation of GGK(FITC) to sHb.
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150 minutes and was analyzed both with ESI-MS and SDS-PAGE. By measuring the fluorescence
in the gel as well as staining the gel with Coomassie stain we were able to monitor any changes
among all of the proteins present as well as those that were modified with a fluorescent label.
During the course of the reaction the migration of the cp- bands stayed constant, whereas the
fluorescence intensity of the small GGK(FITC) linker decreased and the larger di-(FITC) band
increased (Figure 12). In addition, from ESI-MS we were able to verify the presence of di-(FITC)
as well as calculate the overall reaction yield of 75% (Figure 13).

Figure 12. SDS-PAGE of GGK(FITC) ligation to sHb. Reaction ran for 150 min. Bands present
include GGK(FITC) with a mass of 685.71 Da, cp- with a mass of 16,532 Da, sortase A with a
mass of 17,851 Da, di-(FITC) with a mass of 32,052 Da, and di- with a mass of 32,361 Da.
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Figure 13. ESI-MS of GGK(FITC) ligation to sHb. A sample was analyzed before addition of
GGK(FITC) (control) and again after 150 min. Peaks present in the spectra include cp- with an
expected mass of 16,532 Da, di-(FITC) with an expected mass of 32,052 Da, di- with an
expected mass of 32,361 Da and the double charge of cp- with an expected mass of 33,064
Da.
Sortase-mediated ligation of GGK(DBCO) to sHb. Once we demonstrated that the
sortase-mediated ligation to sHb worked, we then wanted to add the strained cyclooctyne
(DBCO) to sHb (Figure 14). Since there is no fluorescent tag in this reaction the SDS-PAGE
results are less informative due to the small molecular weight difference between di- and di(DBCO) (Figure 15). However, the successful ligation of DBCO to sHb was suggested by ESI-MS,
which showed a prominent peak at 31,952 Da, which is just slightly below the expected mass of

Figure 14. Sortase-mediated ligation of GGK(DBCO) to sHb.
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Figure 15. SDS-PAGE of GGK(DBCO) ligation to sHb followed by purification. The reaction ran for
120 min and was then purified. Samples were collected from the 50 mM imidazole elution as well
as the 250 mM imidazole elution. Bands present include cp- with a mass of 16,532 Da, sortase A
with a mass of 17,851 Da, di-(DBCO) with a mass of 31,969 Da, and di- with a mass of 32,361
Da.
di-(DBCO) of 31,969 Da. The di- peak at 32,361 Da also decreased in intensity and a reaction
yield of 87% product was calculated (Figure 16).
Purification of di-(DBCO) cp- sHb. Following the sortase-meditated ligation of DBCO to
sHb we then wanted to establish that we could purify the desired product from the reaction
mixture. To do this we took advantage of the loss of the hexa-histidine tag from sHb during the
ligation. Due to several histidine residues on the surface of human Hb, Hb naturally has a
moderate binding affinity for Ni2+ IMAC resin. Thus, while di-(DBCO) sHb still had some affinity
for the Ni2+ IMAC column it had a reduced affinity compared to the unligated di- sHb and so
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Figure 16. ESI-MS spectra of GGK(DBCO) ligation to sHb followed by purification. A sample was
analyzed before addition of GGK(DBCO) (control – top left) and again after 120 min (top right).
The reaction mixture was purified with IMAC resulting in a 50 mM imidazole elution of di(DBCO) (bottom left) and 250 mM imidazole elution of di- (bottom right). Peaks present in
the spectra include cp- with an expected mass of 16,532 Da, di-(DBCO) with an expected
mass of 31,969 Da, di- with an expected mass of 32,361 Da and the double charge of cp-
with an expected mass of 33,064 Da.
eluted at a lower imidazole concentration of 50 mM imidazole. The unligated di- sHb eluted
from the Ni2+ column at 250 mM imidazole. The SDS-PAGE showed a slightly lower band at 32
kDa in the 50 mM imidazole lane which suggests the presence of di-(DBCO), while in the
higher imidazole lane, the di- band has slightly retarded mobilty (Figure 15). The expected
lower mass for the purified DBCO-sHb was also confirmed by ESI-MS with a peak at 31,952 Da
for 50 mM imidazole elution sample (Expected mass of di-(DBCO) = 31,969 Da) compared to
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the peak at 32,362 Da for the 250 mM imidazole elution sample (Expected mass of di- =
32,359 Da) (Figure 16).
Cyclooctyne azide conjugation. The last proof-of-concept for the development of our
monodisperse HBOC was the cycloocytne azide conjugation. The reaction was carried out in the
absence of a copper ion catalyst with the addition of 6-FAM-azide to the purified di-(DBCO)
Hb and monitored for 60 min (Figure 17). SDS-PAGE showed that while the migration of the cp-

 band was constant, the band for di- was slightly retarded. Additionally, the fluorescence
intensity at the di- molecular weight increased as the reaction progressed consistent with the
addition of 6-FAM to the di- globin (Figure 18). ESI-MS also showed a peak at 32,415 Da which
is slightly lower than the expected mass of 32,430 Da for di-(DBCO-6-FAM-azide). The
calculated yield was 68% (Figure 19).

Figure 17. Cyclooctyne azide conjugation.
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Figure 18. SDS-PAGE of 6-FAM-azide conjugation to sHb(DBCO). The reaction ran for 60 min.
Bands present include cp- with a mass of 16,532 Da, di-(DBCO) with a mass of 31,969 Da,
and di-(DBCO-6-FAM-azide) with a mass of 32,430 Da.

Figure 19. ESI-MS of 6-FAM-azide conjugation to sHb(DBCO). A sample was analyzed before
addition of 6-FAM-azide (control) and then the reaction ran for 60 min. Peaks present in the
spectra include cp- with an expected mass of 16,532 Da, di-(DBCO) with an expected mass of
31,969 Da, di-(DBCO-6-FAM-azide) with an expected mass of 32,430 Da and the double
charge of cp- with an expected mass of 33,064 Da.
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Crystallization and X-ray
diffraction. A total of 31 crystal trays were
made with the hanging drop method and a
variety of buffer (mother liquor)
5 mg/ml
1:1 Protein:Buffer
PEG 3350 28%
0.1 M Bis Tris pH 5.8
4ºC

5 mg/ml
1:1 Protein:Buffer
PEG 3350 24%
0.1 M Bis Tris pH 5.8
4ºC

Figure 20. Crystal conditions with varying PEG
concentration.

compositions. Almost all trays were made
with a maximum protein concentration of
5 mg/mL because at higher concentrations
Hb precipitated out of solution. The ratio

of protein to buffer added to the hanging drop was 1:1 or 1:2 for the same buffer conditions.
The pH of the buffer, 0.1 M Bis Tris, varied from 5.8-7.5. The largest crystals with the best
structure were obtained in conditions where the buffer pH was between 5.8-6.2 (Figures 2022). Polyethylene glycol (PEG) 3350 was added with varying amounts ranging from 18-33%
(w/v). Larger crystals with better
morphology were obtained when the
PEG concentrations was 22-28% (Figure
20-21).
Various salts were added such
as sodium chloride, ammonium acetate,
and ammonium sulfate which resulted
in crystals with different geometric
structures compared to those obtained

5 mg/ml
1:1 Protein:Buffer
PEG 3350 22%
0.1 M Bis Tris pH 6.0
10 mM NaCl
4ºC

5 mg/ml
1:1 Protein:Buffer
PEG 3350 22%
0.1 M Bis Tris pH 6.0
20 mM (NH4)2SO4
4ºC

Figure 21. Crystal conditions with the addition
of sodium or ammonium sulfate.
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without added salt. In the absence of added salt the crystals had a square geometry with a large
surface area.
With the addition of salt, the crystals formed were long, thin and rectangular. Among
the different salts conditions tested, the addition of ammonium sulfate resulted in the largest
crystals with the best morphology (Figure 21). To reduce precipitation, crystal growth was
slowed by adding Al’s oil to some of the crystal trays, as well as reducing the temperature at
which the trays were made and stored from 25C to 4 C (Figure 22).
Crystals with red color, regular
morphology, and noticeably larger size
were looped and frozen for X-ray
diffraction. With the help of Professor
Clint Speigel, crystals were mounted in
the diffractometer and the diffraction
images were collected. Unfortunately,
none of these crystals diffracted with

5 mg/ml
1:1 Protein:Buffer
PEG 3350 28%
0.1 M Bis Tris pH 6.2
4ºC

5 mg/ml
1:1 Protein:Buffer
PEG 3350 28%
0.1 M Bis Tris pH 6.1
25ºC

Figure 22. Crystal conditions at different
temperatures.

sufficient resolution for protein structure
determination.

Discussion
While the development of a monodisperse, oligomeric HBOC is by no means complete,
the initial experiments reported here demonstrate the potential of our approach. We have
established proof-of-concept for linking DBCO-modified Hb molecules to a scaffold that displays
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azide groups. This proof-of-concept was achieved in a stepwise fashion by testing a series of
reactions that could be easily monitored.
One of the biggest concerns that needs to be resolved is the low expression yield of ~1.0
mg/mL for the sHb construct. A large reason for this low expression is the inclusion of cp-
globin into the sHb construct, which is known to have a reduced expression in comparison to wt

 globin. This –globin variant was used in these initial experiments in the interest of time: we
had expression vectors with the cp- gene readily available. Now that we have established
proof-of-concept for sortase A’s ability to modify Hb, we will create an alternate version of sHb
that co-expresses a wild-type (wt)  globin with the sortase-tag di- globin. With the addition
of wt  the expression of sHb should increase dramatically (in our experience by > 10-fold). In
the unlikely chance that expression does not increase, the sortase tag on the di- globin may be
inhibiting expression. Other ways to optimize the expression yields include changing the
amount of time the cells are grown, changing the temperature during the growth, or including
additional nutrients. Increasing expression is necessary to support future preclinical testing of
polymeric Hbs.
Once expressed and purified the sHb contruct was easily modified with reactions that
produced good yields. While the yield for each reaction could be improved, the cyclooctyne
azide conjugation has the most room for optimization. To increase product formation the
reaction could continue for a longer period of time, and the linker, 6-FAM-azide, could be used
in greater excess, such as 3x, 5x, 10x. Although tractable in the near-term, requiring a large
excess of the azide reagent is not desirable; thus, optimizing yields through changes in reaction
conditions will be a top priority.
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To optimize the sortase-mediated reactions, more focus should be placed on minimizing
side reactions. Side reactions that could be occurring include the reverse reaction which results
in the re-formation of the starting sHb as well as formation of a hydrolysis product (Figure 23).
The reverse reaction occurs when the cleaved peptide with an N-terminal glycine acts as a
nucleophile and reforms the starting material. To prevent this, a 2x excess of the linker peptide
is added in order to push the reaction forward. Another strategy to minimize the reverse
reaction is to add nickel to the reaction mixture which can then chelate with the cleaved
peptide to prevent it from reacting30. There are fewer options for preventing the hydrolysis
product.

Figure 23. Side reactions during sortase-mediated ligations.
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However, based on the initial experiments described above, it does not seem to be a significant
problem for ligations with sHb. Only a small fraction of the total di- added to the reaction
appears to form the hydrolysis product.
The next steps for the development of this HBOC are to conjugate sHb to a larger azide
scaffold. First, sHb conjugation to a small azide tetramer will be tested, followed by increasingly
larger azide scaffolds. We anticipate that the structure of the scaffold will need to be optimized
to allow multiple high molecular weight proteins to react with the azide groups. Commercially
available scaffolds will be tested first, but these reagents have relatively short arms that may
sterically prevent multiple ligations with Hb. Furthermore, it will be necessary to test the
oxygen binding affinities of the therapeutic as it is developed to verify that it can reversibly bind
oxygen. If as expected, the product has high oxygen binding affinity, the mutant N108K can be
incorporated into the protein, therefore reducing the oxygen affinity to a physiologicallyfunctional level.
In support of efforts to modulate poly-Hb oxygen binding, we undertook structural
studies of N108K mutants. We have not yet obtained suitable diffraction data. In order to get a
high-resolution X-ray data set, the production of N108K Hb crystals needs to be further
optimized. While crystal nucleation is not an issue, the formation of crystals that are large
enough with good morphology for crystallography is needed. With the conditions sampled,
crystals are able to form but many have irregular morphology or a small size. For the time
being, this effort will be suspended until we narrow down the Hb variant that is optimal for the
sortase ligation work.
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Through rational design that combines genetic and chemical modifications, our strategy
to generate an HBOC shows potential to provide a functional oxygen carrier for acute blood
replacement. Employing sortase A to add a highly-specific, biocompatible DBCO functional
group to Hb allows us to explore the potential of “click chemistry” to generate a monodisperse
poly-Hb. Moreover, by investigating mutations to decrease oxygen affinity, our product will
have increased capability of transporting oxygen.
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Appendix
Table A1. Crystal Tray Conditions
Tray

[Protein]

Protein:Buffer

Temperature
°C

Column Condition

Variance

Row Condition

Variance

Other

1

5

1:1

25

0.1 M Bis Tris pH

5.9, 6.0, 6.1, 6.2

PEG 3350 (%)

25, 26, 27, 28, 29, 30

none

2

5

1:1

25

0.1 M Bis Tris pH

5.9, 6.0, 6.1, 6.2

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

3

5

1:1, 1:2

25

0.1 M Bis Tris pH

5.75, 6.05,6.6,7.0

PEG 3350 (%)

26, 28, 30, 32, 34 , 36

none

4

5

1:1, 1:2

25

0.1 M Bis Tris pH

6.05,6.3,6.4, 6.6

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

5

5

1:2, 1:3

25

0.1 M Bis Tris pH

6.05,6.3,6.4, 6.6

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

6

3

1:1, 1:2

25

0.1 M Bis Tris pH

6.05, 6.3, 6.4, 6.6

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

7

5

1:1, 1:2

25

0.1 M Bis Tris pH

6.0, 6.3, 6.5, 6.8

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

8

5

1:1, 1:2

25

0.1 M Bis Tris pH

6.0, 6.3, 6.5, 6.8

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

9

5

1:1, 1:2

25

NaCl (mM)

0, 10, 15, 20

PEG 3350 (%)

28, 29, 30, 31, 32, 33

0.1 M Bis Tris pH 6.0

10

5

1:1

25

NaCl (mM)

0, 10, 15, 20

PEG 3350 (%)

28, 29, 30, 31, 32, 33

0.1 M Bis Tris pH 6.8

11

5

1:1

25

0.1 M Bis Tris pH

6.0, 6.3, 4.4, 6.6

PEG 3350 (%)

28, 29, 30, 31, 32, 33

Al's oil

12

5

1:1

25

0.1 M Bis Tris pH

6.0, 6.3, 4.4, 6.6

PEG 3350 (%)

28, 29, 30, 31, 32, 33

none

13

5

1:1

4

NaCl (mM)

0, 5, 10, 20

PEG 3350 (%)

28, 29, 30, 31, 32, 33

0.1 M Bis Tris pH 6.0

14

5

1:1

4

NaCl (mM)

0, 5, 10, 20

PEG 3350 (%)

18, 20, 22, 24, 26, 28

0.1 M Bis Tris pH 6.0

15

5

1:1

4

0.1 M Bis Tris pH

5.8, 6.0, 6.2, 6.4

PEG 3350 (%)

18, 20, 22, 24, 26, 28

none

16

10

1:1

4

0.1 M Bis Tris pH

5.8, 6.0, 6.2, 6.4

PEG 3350 (%)

18, 20, 22, 24, 26, 28

none

17

5

1:1, 1:2

4

NaCl (mM)

10, 20, 30, 40

PEG 3350 (%)

22, 24, 26, 28, 30, 32

0.1 M Bis Tris pH 6.0

18

5

1:1, 1:2

4

(NH4)2SO2

0, 5, 10, 20

PEG 3350 (%)

22, 24, 26, 28, 30, 32

0.1 M Bis Tris pH 6.0

19

5

1:1

4

(NH4)2SO2

0, 5, 10, 20

PEG 3350 (%)

22, 24, 26, 28, 30, 32

0.1 M Bis Tris pH 6.0

20

5

1:1, 1:2

4

NaCl (mM)

0, 20, 40, 60

PEG 3350 (%)

22, 24, 26, 28, 30, 32

0.1 M Bis Tris pH 6.0

21

5

1:1, 1:2

4

(NH4)2SO2

0,10, 20, 30

PEG 3350 (%)

22, 24, 26, 28, 30, 32

0.1 M Bis Tris pH 6.0

22

5

1:1, 1:2

4

(NH4)2SO2

0,10, 20, 30

0.1 M Bis Tris pH

5.8, 6.1, 6.4, 6.7, 7.0, 7.5

24% PEG

23

5

1:1, 1:2

4

PEG 3350 (%)

24, 26, 28, 30

NH4(SO2)2

10, 20, 30, 40, 50, 60

0.1 M Bis Tris pH 6.0

24

5

1:1, 1:2

4

(NH4)2SO2

0,10, 20, 30

PEG 3350 (%)

18, 22, 26, 32, 36, 40

0.1 M Bis Tris pH 6.0

25

5

1:1, 1:2

4

0.1 M Bis Tris pH

6.0, 6.2, 6.4, 6.5

NH4(SO2)2

40, 50, 60, 70, 80, 90

24% PEG

26

5

1:1, 1:2

4

PEG 3350 (%)

22,23,24,26

NH4(SO2)2

40, 50, 60, 70, 80, 90

0.1 M Bis Tris pH 6.0

27

5

1:1, 1:2

4

0.1 M Bis Tris pH

6.0, 6.3,6.4, 6.5

PEG 3350 (%)

20, 22, 24, 26, 28, 30

Al's oil

28

5

1:1, 1:2

4

PEG 3350 (%)

20, 22, 24, 26

NH4(SO2)2

0, 20, 40, 60, 80, 100

0.1 M Bis Tris pH 6.5

29

5

1:1, 1:2

4

PEG 3350 (%)

18,20,24,26

NH4(SO2)2

0, 20, 40, 60, 80, 100

0.1 M Bis Tris pH 6.5

30

5

1:1, 1:2

4

PEG 3350 (%)

23, 24, 25, 26

0.1 M Bis Tris pH

6.2, 6.3, 6.4, 6.5, 6.6

none

31

5

1:1, 1:2

4

0.1 M Bis Tris pH

5.9, 6.1,6.27,6.43

PEG 3350 (%)

22, 22, 23, 23, 24, 24

none
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Synthesis and purification of GGK(DBCO). The peptide GGK(DBCO) was successfully synthesized
and purified. After the initial purification with Method A (see Materials and Methods) there was
still residual Fmoc in solution so a second purification was carried out. Better separation of the
DBCO and Fmoc peak was achieved with Method C, and we were able to purify GGK(DBCO) to
>95%.

Figure A1. ESI-MS analysis of GGK(DBCO). Main peak at 546.2 Da confirmed the
presence of GGK(DBCO) which has an expected mass of 546.26 Da.

Figure A2. HPLC spectra of GGK(DBCO). The main peaks seen both at 280 nm and 309 nm
confirm purity of GGK(DBCO) purity.
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